NEO shows concerning operational performance deterioration with meaningfully higher losses despite substantial debt reduction and improved liquidity position.
The company's net losses expanded meaningfully while operating losses also increased, indicating ongoing operational challenges despite cost management efforts. However, the substantial reduction in debt and current liabilities suggests active balance sheet restructuring, though this came at the cost of depleting cash reserves by over half.
NEO's financial profile reflects a company undergoing significant restructuring with mixed results. The balance sheet strengthened notably through substantial debt reduction and lower current liabilities, but cash reserves declined significantly from $367M to $160M, indicating this deleveraging required substantial cash deployment. Operating performance deteriorated with higher net and operating losses alongside increased R&D spending, while reduced capital expenditures and lower operating cash flow suggest constrained investment capacity despite the balance sheet improvements.
Current liabilities reduced — improved short-term financial position and working capital health.
Cash declined 56.5% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.
Net income declined 37.2% — review whether driven by operations, interest costs, or non-recurring items.
Current assets declined 36.9% — monitor working capital adequacy and short-term liquidity.
Debt reduced 36.8% — deleveraging strengthens balance sheet and reduces financial risk.
Capex reduced 34.2% — investment cycle winding down or capital discipline; may improve near-term free cash flow.
Liabilities reduced 28.9% — deleveraging improves balance sheet strength and financial flexibility.
Operating profitability softening — costs rising faster than revenue, watch for margin recovery plan.
Operating cash flow softened — monitor whether temporary working capital timing or structural deterioration.
R&D investment increased 19% — signals commitment to future product development, though near-term margin impact.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →